Uptravi (selexipag) 200 micrograms film-coated tablets, 140 tablets — original (Janssen) Uptravi. Delivery of medications from Europe and beyond within 4-5 days, storage conditions observed, payment upon receipt. Order by calling +380996042415, Viber, WhatsApp.

Uptravi is indicated for the long-term treatment of pulmonary arterial hypertension (PAH) in adult patients with WHO functional class (FC) II-III, either as combination therapy in patients inadequately controlled with an endothelin receptor antagonist (ERA) and/or phosphodiesterase type 5 (PDE-5) inhibitor, or as monotherapy in patients who are not candidates for these therapies.

Efficacy has been demonstrated in a PAH population, including idiopathic and hereditary PAH, PAH associated with connective tissue disorders, and PAH associated with corrected simple congenital heart disease.

Treatment should be initiated and monitored only by a physician experienced in the treatment of PAH.

Dosage

Individual Dose Titration

Each patient should be advised of the highest individually tolerated dose, which may range from 200 mcg administered twice daily to 1600 mcg administered twice daily (individual maintenance dose).

The recommended starting dose is 200 mcg twice daily, approximately 12 hours apart. The dose is increased in 200 mcg increments twice daily, usually at weekly intervals. At the start of treatment and during each up-titration, it is recommended to take the first dose in the evening. During titration, some adverse reactions may occur, reflecting Uptravi's mode of action (such as headache, diarrhea, nausea and vomiting, jaw pain, myalgia, extremity pain, arthralgia, and hot flashes). These are usually transient or manageable with symptomatic treatment. However, if the patient reaches an intolerable dose, the dose should be reduced to the previous dose level.